Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Radicava’s Brazil Launch Set for February 29: Mitsubishi Tanabe
February 28, 2024
- Insmed Revs Up for Product Expansion in Japan, Arikayce Frontline Filing Set for 2026 with More to Follow
February 28, 2024
- Japan Drug Market Tops 11 Trillion Yen for 1st Time Driven by Oncologics: IQVIA
February 27, 2024
- Shionogi Seeks Japan Nod for Akili’s Therapeutic App for Kids with ADHD
February 27, 2024
- BMS Files Ulcerative Colitis Med Ozanimod in Japan
February 27, 2024
- Chugai Tapping Wearable to Objectively Gauge Pain, First Eyes Endometriosis Trial
February 26, 2024
- Novel Antibiotic Fetroja Approved in Taiwan: Shionogi
February 26, 2024
- Maruho’s China Subsidiary Now Up and Running
February 26, 2024
- Economic Terms for Obesity Drug Deal Disclosed by Lilly: Chugai
February 26, 2024
- As Wegovy Hits Japan Market, Novo Re-Stresses Need for Proper Use
February 26, 2024
- Astellas CTO Eager to “Democratize” Digital Tools to Boost Productivity
February 21, 2024
- CureApp Kicks Off Japan PIII Study for NASH Therapeutic App
February 21, 2024
- Mitsubishi Tanabe Files OD Tablet Form for Canalia in Japan
February 21, 2024
- Gilead Japan Ramping Up Sales Force with Trodelvy Now under Review
February 20, 2024
- Ono, InveniAI Pair Up for AI-Powered Drug Discovery
February 20, 2024
- Kyowa Kirin’s Phozevel Now Available for Hyperphosphatemia
February 20, 2024
- Daiichi Sankyo’s TROP2 ADC Now under US FDA Review for Lung Cancer
February 20, 2024
- Active Pharma Hid Botched API Production, Source Reveals Details of Violations
February 19, 2024
- Sawai Group President Says US Biz Exit was Due to Lack of Foresight
February 19, 2024
- Vital KSK, 3 Other Firms Invest in LinDo to Drive Japan Launch of Innovative Drugs
February 19, 2024
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…